Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Nov;60(5):789–792. doi: 10.1038/bjc.1989.361

A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma.

J J Keating 1, P J Johnson 1, A M Cochrane 1, B G Gazzard 1, N Krasner 1, P M Smith 1, P N Trewby 1, P Wheeler 1, S P Wilkinson 1, R Williams 1
PMCID: PMC2247314  PMID: 2529892

Abstract

In a prospective controlled clinical trial, 108 patients with pancreatic adenocarcinoma were randomly allocated to receive tamoxifen 20 mg b.d., cyproteron acetate 100 mg t.d.s. or no active treatment. The median survival of those receiving tamoxifen was longer than either of the other two groups (5.25 compared to 4.25 and 3 months, respectively) but this difference did not achieve statistical significance. Cox regression analysis of 12 clinical and biochemical features showed that, for the entire group of patients, survival was significantly longer in younger patients, those undergoing surgical bypass and those with better initial performance status. However, even when adjustment was made to allow for the distribution of these prognostic variables within the three groups, the difference in survival still did not achieve statistical significance. No side-effects attributable to treatment was observed.

Full text

PDF
790

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki K., Ogawa H. Cancer of the pancreas, international mortality trends. World Health Stat Q. 1978;31(1):2–27. [PubMed] [Google Scholar]
  2. Carter S. K., Comis R. L. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev. 1975 Sep;2(3):193–214. doi: 10.1016/s0305-7372(75)80003-x. [DOI] [PubMed] [Google Scholar]
  3. Gonzalez-Barcena D., Rangel-Garcia N. E., Perez-Sanchez P. L., Gutierrez-Damperio C., Garcia-Carrasco F., Comaru-Schally A. M., Schally A. V. Response to D-Trp-6-LH-RH in advanced adenocarcinoma of pancreas. Lancet. 1986 Jul 19;2(8499):154–154. doi: 10.1016/s0140-6736(86)91961-6. [DOI] [PubMed] [Google Scholar]
  4. Greenway B., Duke D., Pym B., Iqbal M. J., Johnson P. J., Williams R. The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br J Surg. 1982 Oct;69(10):595–597. doi: 10.1002/bjs.1800691013. [DOI] [PubMed] [Google Scholar]
  5. Greenway B., Iqbal M. J., Johnson P. J., Williams R. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J (Clin Res Ed) 1981 Sep 19;283(6294):751–753. doi: 10.1136/bmj.283.6294.751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gudjonsson B., Livstone E. M., Spiro H. M. Cancer of the pancreas: diagnostic accuracy and survival statistics. Cancer. 1978 Nov;42(5):2494–2506. doi: 10.1002/1097-0142(197811)42:5<2494::aid-cncr2820420554>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  7. KARNOFSKY D. A. Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther. 1961 Nov-Dec;2:709–712. doi: 10.1002/cpt196126709. [DOI] [PubMed] [Google Scholar]
  8. Redding T. W., Schally A. V. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A. 1984 Jan;81(1):248–252. doi: 10.1073/pnas.81.1.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Satake K., Yoshimoto T., Mukai R., Umeyama K. Estrogen receptors in 7,12-dimethylbenz (a) anthracene (DMBA) induced pancreatic carcinoma in rats and in human pancreatic carcinoma. Clin Oncol. 1982 Mar;8(1):49–54. [PubMed] [Google Scholar]
  10. Sica V., Nola E., Contieri E., Bova R., Masucci M. T., Medici N., Petrillo A., Weisz A., Molinari A. M., Puca G. A. Estradiol and progesterone receptors in malignant gastrointestinal tumors. Cancer Res. 1984 Oct;44(10):4670–4674. [PubMed] [Google Scholar]
  11. Theve N. O., Pousette A., Carlström K. Adenocarcinoma of the pancreas--a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol. 1983 Sep;9(3):193–197. [PubMed] [Google Scholar]
  12. Tønnesen K., Kamp-Jensen M. Antiestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol. 1986 Mar;12(1):69–70. [PubMed] [Google Scholar]
  13. Wong A., Chan A., Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):749–750. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES